Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HNSCC for Phase 2 Dose Expansion”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Testing effectiveness (Phase 2)Looking for participantsNCT06747585
What this trial is testing

Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Who this might be right for
Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell Carcinoma+1 more
Alentis Therapeutics AG 170
Testing effectiveness (Phase 2)Study completedNCT03744468
What this trial is testing

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-inHNSCC for Phase 2 Dose ExpansionNSCLC for Phase 2 Dose Expansion
BeiGene 147
Testing effectiveness (Phase 2)Study completedNCT04616196
What this trial is testing

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaColorectal Cancer
Nektar Therapeutics 25